Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025
•Cash runway extended into the second half of 2026 •Average sales price per share was over 10% higher than the June 2025 public offering price Intensity Therapeutics, Inc. (Nasdaq: INTS) (“Intensity” or “the Company”), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill […]